There were three dose levels in the study, namely 300mg, 700mg and 1,000mg and results were measured according to American College of Rheumatology (ACR) criteria.
In the 300mg dose group, 25% of patients achieved ACR50 and 13% achieved ACR70. In the 700mg dose group, 44% of patients achieved ACR50 and 22% achieved ACR70. Finally, in the 1,000mg dose group, 44% of patients achieved ACR50 while 11% achieved ACR70.
After re-examination of the previously reported ACR20 data, Genmab also reported that it appears one of the responders in the 300mg dose group had received only one dose of HuMax-CD20, thus 73% of patients treated with two doses of HuMax-CD20 achieved ACR20. The intent to treat analysis remains the same, with 63% of patients achieving ACR20.
“These ACR50 and ACR70 results look very promising,” commented Dr Lisa Drakeman, CEO of Genmab, “and we are looking forward to future development of the product.”
The data were presented at the tenth anniversary Inflammation and Immune Diseases, Drug Discovery and Development Summit in New Brunswick, New Jersey.